A Potential Role of Interleukin 10 in COVID-19 Pathogenesis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

(2020) Zhe Xu et al.   Lancet Respiratory Medicine

SARS-CoV-2 and viral sepsis: observations and hypotheses

(2020) Hui Li et al.   LANCET

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

(2020) Bo Diao et al.   Frontiers in Immunology

Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease

(2020) Yan Zhao et al.   JCI Insight

The laboratory tests and host immunity of COVID-19 patients with different severity of illness

(2020) Feng Wang et al.   JCI Insight

Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?

(2020) Ligong Lu et al.   Frontiers in Cell and Developmental Biology

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

(2018) Aung Naing et al.   CANCER CELL

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors

(2016) Aung Naing et al.   JOURNAL OF CLINICAL ONCOLOGY